CEEPC/IPM/CMSC - Abstrakt prezentace

(CEEPC/IPM/CMSC 2022 - SaO-23)
Cardiac alarmins as residual risk markers of atherosclerosis under lipid-lowering therapy

Viorel-Iulian Suica 1, Elena Uyy 1, Luminita Ivan 1, Raluca Maria Boteanu 1, Felicia Antohe 1 *

  1. Proteomics Department, Institute of Cellular Biology and Pathology "Nicolae Simionescu", Romania

Abstrakt

Background: The major cause in the initiation and progression of atherosclerosis are the high levels of low-density lipoproteins. Although statin treatment can effectively lower these levels, there is still a residual risk of cardiovascular events. We hypothesize that a specific panel of alarmins, a family of stress-sensing molecules, could indicate the persistence of silent atherosclerosis residual risk.
Methods: New Zeeland White rabbits were divided into: the control group (C) with standard diet, a group which received a high-fat diet for 12 weeks (Au) and a treated hyperlipidemic group, with a lipid diet for 8 weeks followed by standard diet and hypolipidemic treatment (atorvastatin and PCSK9 siRNA-inhibitor) for 4 weeks (Asi). We used the LTQ Orbitrap Velos Pro mass spectrometer to analyse the left ventricle lysates. The experiments were complemented by immunologic and genomic assays to corroborate the data.
Results: The hyperlipidemic diet determined a general alarmin up-regulation tendency over C group. A significant spectral abundance increase was measured for specific heat shock proteins, S100 family members, HMGB1 and Annexin A1. The hypolipidemic treatment demonstrated a reversed regulation trend, with non-significant spectral alteration over the C group for some identified alarmins.
Conclusion: Our study highlights the discriminating potential of alarmins in hyperlipidemia or following a hypolipidemic treatment.

* Korespondující autor: felicia.antohe@icbp.ro

Poděkování:

Romanian Academy, CCCDI-UEFISCDI project COFUND-ERA-CVD-XploreCAD, within PNCDI III and grants from the MRID CNCS - UEFISCDI, PN-III-P4-PCE-2021-1344 and PN-III-P1-1.1-TE-2021-1161 within PNCDI III.


Partneři společnosti

LabRules LCMS LabRules GCMS

Partneři

Bruker HPST Merck Pragolab Amedis EastPort Shimadzu Waters